ESTRO 2025 - Abstract Book

S1602

Clinical – Mixed sites & palliation

ESTRO 2025

Conclusion: SBRT is reported to be well-tolerated in the current literature and should be considered as a treatment option for intra-cardiac tumors and metastases . Prospective trials are needed to establish standardized treatment protocols.

Keywords: intra-cardiac tumors, cardiac metastases, SBRT

References: 1 Hudzik B., Miszalski-Jamka K., Glowacki J. Malignant tumors of the heart. Cancer Epidemiol. 2015;39(5):665 – 672. doi: 10.1016/j.canep.2015.07.007. 2 Corradini S, von Bestenbostel R, Romano A, et al. MR-guided stereotactic body radiation therapy for primary cardiac sarcomas. Radiat Oncol. 2021;16(1):60. Published 2021 Mar 26. doi:10.1186/s13014-021-01791-9 *Contributed equally

4444

Digital Poster Delineation of Supraclavicular Lymph Node Levels in Abdominopelvic Tumors: Insights from the ‘Block Reflux’ Lymphatic Pathway— A Retrospective Study Jielin Wei 1,2,3 , Guiling Li 1,2 , Yu Chang 1,2 , Shujie Wang 1,2 , Kunyu Yang 1,2 , Yingchao Zhao 1,2 1 Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. 2 Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. 3 Clinical Cooperation Unit Translational Radiation Oncology (E210), National Center for Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany Purpose/Objective: The significant involvement of left-sided supraclavicular lymph nodes (LSCLNs) in abdominopelvic malignancies, accounting for over 30%, necessitates precise and individualized clinical target volume (CTV) delineation. However, current guidelines based on lymphatic pathways of head and neck or breast cancers, fundamentally differ from the “block - reflux lymphatic pattern” in jugular -subclavian junction of abdominopelvic cancer patients.